ArticleThrombosis journal2026
High thrombotic burden in severe Chinese wAIHA patients: a single-center retrospective study.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with warm autoimmune hemolytic anemia (wAIHA) have an established high risk of thrombosis. However, emerging data from Asia, particularly a recent Japanese study, challenge this paradigm. This study aimed to characterize thrombotic events and identify associated risk factors in a cohort of Chinese patients with wAIHA.
methodsRetrospective analysis of 32 wAIHA patients admitted to Wuhan Hospital of Traditional Chinese and Western Medicine (2020–2024).
resultsThe cohort comprised 32 wAIHA patients with a median age of 65 years and follow-up of 27 months, comprising 24 (75%) newly diagnosed and 8 (25%) relapsed cases, of which 53% were primary and 47% secondary. After treatment, 19 patients achieved clinical remission, 12 had partial remission, and 1 died from pulmonary embolism. Eight patients (25%) experienced 12 thrombotic events during acute hemolysis: deep vein thrombosis (5), pulmonary embolism (3), acute cerebral infarction (2), disseminated intravascular coagulation (1), and lower limb arterial embolism (1). Comparative analysis showed thrombotic patients had relatively lower hemoglobin (55.88 g/L vs. 74.87 g/L, p = 0.031) and higher lactate dehydrogenase (1064 U/L vs. 439 U/L, p = 0.045) than non-thrombotic patients. No significant differences were found in platelet count, D-dimer, antinuclear antibody, or Padua scores. Significant differences were noted in therapeutic anticoagulation (p < 0.001) and therapeutic plasma exchange (p = 0.023), but not in prophylactic anticoagulation (p = 0.250).
conclusionsIn Chinese wAIHA cohort, thrombosis during acute hemolysis was common and linked to markers of severe disease (low hemoglobin, high LDH, plasma exchange). This distinct high-thrombosis phenotype indicates potential limitations of standard risk tools, necessitating prospective studies for tailored risk stratification and thromboprophylaxis evaluation in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.